Diagnostic Mutations ID'd in Chronic Kidney Disease Patients

Share this content:
Diagnostic Mutations ID'd in Chronic Kidney Disease Patients
Diagnostic Mutations ID'd in Chronic Kidney Disease Patients

TUESDAY, Dec. 5, 2017 (HealthDay News) -- About one-quarter of adults with chronic kidney disease (CKD) of unknown cause or familial nephropathy or hypertension have diagnostic mutations, which can be identified with whole-exome sequencing (WES), according to a study published online Dec. 5 in the Annals of Internal Medicine.

Sneh Lata, Ph.D., from Columbia University in New York City, and colleagues examined the diagnostic utility of WES in a cohort of 92 adults with CKD of unknown cause or familial nephropathy or hypertension.

The researchers found that WES provided a diagnosis in 24 percent of patients, including nine probands with CKD of unknown cause encompassing 13 distinct genetic disorders. In two probands with tubulointerstitial fibrosis, loss-of-function mutations were identified in PARN; these findings extend the phenotype of PARN mutations to renal fibrosis. A pathogenic BRCA2 mutation was identified in a proband who was diagnosed with breast cancer on follow-up. In most solved cases the results affected clinical management, including initiation of targeted surveillance, familial screening to guide selection of a donor for transplantation, and alterations in therapy.

"Whole-exome sequencing identified diagnostic mutations in a substantial number of adults with CKD of many causes," the authors write. "Further study of the utility of WES in the evaluation and care of patients with CKD in additional settings is warranted."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »